Survival prediction in acute myeloid leukemia using gene expression profiling

Table1 Association between the clinical features and patients’ mortality in 171 AML patients of the TCGA dataset

Variables	Group	Alive	Dead	P value	Statistical method
Age		49.63	58.86	0.00	Student t test
PBMBC		44.25	40.28	0.48	Student t test
Gender	Female	21	50	0.86	Fisher’s exact test
Gender	Male	27	59	0.86
European Leukemia Net classification	Favorable	10	7	0.03	Fisher’s exact test
	Intermediate	30	72
	Poor	8	28
TP53 mutation	Mutant	0	14	0.003	Fisher’s exact test
TP53 mutation	Wild-type	59	100
ASXL1 mutation	Mutant	0	3	0.55	Fisher’s exact test
ASXL1 mutation	Wild-type	59	111
RUNX1 mutation	Mutant	3	13	0.27	Fisher’s exact test
RUNX1 mutation	Wild-type	56	101
IDH1 mutation	Mutant	7	9	0.26	Fisher’s exact test
IDH1 mutation	Wild-type	41	100
IDH2 mutation	Mutant	5	12	1	Fisher’s exact test
IDH2 mutation	Wild-type	43	97
DNMT3A mutation	Mutant	10	33	0.25	Fisher’s exact test
DNMT3A mutation	Wild-type	38	76
NP1 mutation	Mutant	15	33	1	Fisher’s exact test
NP1 mutation	Wild-type	33	76
CEBPA mutation	Mutant	4	9	1	Fisher’s exact test
CEBPA mutation	Wild-type	44	100
FLT3 mutation	Mutant	12	32	0.7	Fisher’s exact test
FLT3 mutation	Wild-type	36	77
Neoadjuvant treatment	Yes	12	31	0.7	Fisher’s exact test
Neoadjuvant treatment	No	36	78

ISSN: 1472-6947